News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (343 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (16 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (41 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 297 of 400 items have one.
Biological clock based on blood measurements predicts mouse lifespan and frailty
NIA investigators have created a biological clock for mice based on blood measurements. Learn how the clock can help predict differences in aging and how the findings could translate to clinical practice.
Why it matters: NIA investigators created a biological clock for mice based on blood measurements that helps predict differences in aging and could translate to clinical practice.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchiveA gene guiding brain cell growth may regulate Alzheimer’s plaque size and toxicity
Plexin-B1 shapes glial networks around beta-amyloid plaques. An NIA-funded study has found that targeting it may improve plaque clearance and reduce brain inflammation.
Why it matters: Targeting Plexin-B1 may improve beta-amyloid plaque clearance and reduce brain inflammation, offering a potential path to regulate Alzheimer's plaque size and toxicity.
Read at NIH National Institute on Aging → Archived copy (2 Oct 2026), Internet ArchiveNew drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
A new drug targeting synaptic resilience shows potential in treating Alzheimer’s disease in an NIA-funded study, with early trials indicating safety and possible brain damage reduction. Further research is needed on the drug’s long-term effects.
Why it matters: An NIA-funded study shows a new Alzheimer's drug candidate targeting synaptic resilience is well tolerated in early trials and may reduce brain damage.
Scientists develop improved mouse model for studying systemic aging-related health decline
NIA scientists developed an improved mouse model to study aging-related health decline, revealing how inflammation drives organ damage.
Why it matters: NIA scientists developed an improved mouse model to study aging-related health decline, revealing how inflammation drives organ damage.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.